Soft Tissue Sarcoma — Expanded Access Programs
Overview
Right2Hope maintains a directory of 32 expanded access programs, clinical trials, and compassionate use pathways listed for Soft Tissue Sarcoma. Each entry below was sourced from sponsor disclosures and public clinical-trial registries. Use this hub to understand the breadth of ongoing research, identify sponsors with soft tissue sarcoma programs, and link out to specific protocols for eligibility, contact, and request details. Of these, 15 programs are currently active or recruiting, with the remaining 17 in other lifecycle stages. Sponsors actively running programs in this area include M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, John Rieth, National Cancer Institute (NCI), University of Wisconsin, Madison, and others.
By recruiting status
Snapshot of where every Soft Tissue Sarcoma program currently sits in its lifecycle.
- Active / Recruiting15
- Inactive17
Top sponsors
Organisations running the most Soft Tissue Sarcoma programs in the directory.
- M.D. Anderson Cancer Center3 programs
- Memorial Sloan Kettering Cancer Center3 programs
- John Rieth2 programs
- National Cancer Institute (NCI)2 programs
- University of Wisconsin, Madison2 programs
- Alexander Z. Wei, MD1 program
- Aveni Foundation1 program
- Children's National Research Institute1 program
- Eli Lilly and Company1 program
- Esperas Pharma Inc.1 program
Soft Tissue Sarcoma programs (32)
Sorted by recruiting status, then alphabetically by program name. Click any program to view eligibility, locations, and sponsor contact details.
- Study on MT-4561 for Patients with Advanced Solid Tumors — Mitsubishi Tanabe Pharma America Inc.
- Study on Cabozantinib-S-Malate for Treating Young Patients with Sarcomas, Wilms Tumor, or Other Rare Tumors — National Cancer Institute (NCI)
- Study on AL3818 and Nivolumab for Treating Advanced Solid Tumors — Sarcoma Oncology Research Center, LLC
- Study on Using Hypofractionated Radiotherapy for Treating Soft Tissue Sarcomas — University of Wisconsin, Madison
- Study on LN-145 or LN-145-S1 for Treating Patients with Certain Types of Cancer That Have Returned or Not Responded to Treatment — M.D. Anderson Cancer Center
- Study on Using Talimogene Laherparepvec Injections Before Surgery for Advanced Soft Tissue Sarcoma — John Rieth
- Phase 2 Study of Zanzalintinib and Pembrolizumab for Certain Types of Advanced Soft-tissue Sarcoma — M.D. Anderson Cancer Center
- Phase II Study of Ribociclib and Everolimus for Advanced Liposarcoma and Leiomyosarcoma — Fox Chase Cancer Center
- Preoperative 5-Day Radiotherapy for Soft Tissue Sarcoma — Medical University of South Carolina
- Study on Radiation Therapy for Treating Bone and Soft Tissue Tumors in Children — St. Jude Children's Research Hospital
- Study on Retifanlimab with Gemcitabine and Docetaxel for Advanced Soft Tissue Sarcoma — Memorial Sloan Kettering Cancer Center
- Phase II Study of Atezolizumab with Chemotherapy and Radiation Before Surgery for High-Risk Soft Tissue Sarcoma — M.D. Anderson Cancer Center
- Study on Talimogene Laherparepvec and Radiation Therapy for Treating Soft Tissue Sarcoma Before Surgery — National Cancer Institute (NCI)
- Study on SPEDOX-6 for Advanced Cancers — University of California, Irvine
- Study on TVEC and Preoperative Radiation for Sarcoma (8 ml Dose) — John Rieth
- 5-Day Preoperative Radiation Treatment for Soft Tissue Sarcoma — Stanford University
- Study on the Effectiveness of Tigilanol Tiglate Injections for Soft Tissue Sarcoma — QBiotics Group Limited
- Pilot Study on Thermodox and MR-HIFU for Treating Relapsed Solid Tumors — Children's National Research Institute
- A Study of Etrumadenant and Zimberelimab in People With Dedifferentiated Liposarcoma — Memorial Sloan Kettering Cancer Center
- Study on LY2880070 for Patients with Advanced or Metastatic Cancer — Esperas Pharma Inc.
- Study on Oral LOXO-292 (Selpercatinib) for Children with Advanced Solid or Brain Tumors — Loxo Oncology, Inc.
- Study on Abemaciclib for Bone and Soft Tissue Sarcoma with CDK Pathway Changes — Medical College of Wisconsin
- Study on APX005M and Doxorubicin for Treating Advanced Soft Tissue Sarcoma — Alexander Z. Wei, MD
- Study on Atezolizumab and Tivozanib for Treating Certain Hard-to-Treat Cancers — University of Florida
- BLESSED: Expanded Access for DNG64 for Advanced Pancreatic Cancer, Sarcoma and Carcinoma of Breast — Aveni Foundation
- Study on Lowering Radiation Dose After Surgery for Soft Tissue Sarcoma in Arms and Legs — Memorial Sloan Kettering Cancer Center
- Study Comparing Two Types of Radiation Therapy for Soft Tissue Sarcomas — University of Wisconsin, Madison
- Study on Injecting IP-001 After Heat Treatment for Patients with Advanced Colorectal, Lung, and Soft Tissue Cancers — Immunophotonics, Inc.
- Study on Nab-Paclitaxel and Gemcitabine for Treating Recurrent or Hard-to-Treat Sarcoma — H. Lee Moffitt Cancer Center and Research Institute
- Study on ADI-PEG 20, Ifosfamide, and Radiation Therapy Before Surgery for Soft Tissue Sarcoma — Washington University School of Medicine
- Olaratumab Access Program for Patients with Soft Tissue Sarcoma — Eli Lilly and Company
- Study on ADI-PEG 20 or Placebo with Gemcitabine and Docetaxel for Previously Treated Leiomyosarcoma Patients — Polaris Group
About this hub
Expanded access programs (sometimes called compassionate use, named-patient programs, or pre-approval access) allow patients with serious or life-threatening conditions such as Soft Tissue Sarcoma to receive an investigational therapy outside of a controlled clinical trial when no comparable approved option is available. Eligibility, location, and the application process differ for each program — review the individual program pages below for sponsor contact information, inclusion criteria, and the request workflow. Right2Hope is a 501(c)(3) nonprofit and provides this directory free of charge for patients, caregivers, and treating physicians.
Looking for a different condition? Browse the full Cancer Type hub directory or search the full expanded access program catalog.